Increased survival of dopaminergic neurons
by rasagiline, a monoamine oxidase B inhibitor
by
Finberg JP, Takeshima T, Johnston JM, Commissiong JW
Department of Pharmacology,
Faculty of Medicine,
Technion, Haifa, Israel.
Neuroreport 1998 Mar 9; 9(4):703-7

ABSTRACT

Both deprenyl and rasagiline (R(+)-N-propargyl-1-aminoindane mesylate), at a concentration of 1-10 microM, increased survival in vitro of rat E14 mesencephalic dopaminergic neurons that had been primed with 10% serum for 12 h (p < 0.05). Rasagiline, but not deprenyl, also increased total neuronal (MAP2-positive) survival (p < 0.05) Under serum-free conditions, rasagiline, but not deprenyl, retained its neuroprotective action on dopaminergic neurones. GABAergic neurons were not affected by either deprenyl or rasagiline. Clorgyline, an MAO-A inhibitor, did not exert any of these effects. The protective action of rasagiline on dopaminergic neurons, even under stringent serum-free conditions, is striking, and warrants further investigation for a role in the treatment of Parkinson's disease.

MAO
GABA
TV3326
Piribedil
Selegiline
Levodopa
Dopamine
Rasagiline
Amphetamines
Propargylamines
Rasagiline: structure
Rasagiline: prospects
Rasagiline and the amines
Parkinson's disease and depression

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family